Research for elucidating the resistance mechanism to RET tyrosine kinase inhibitors in patients with non-small-cell lung cancer harboring with RET fusion gene

Research for elucidating the resistance mechanism to RET tyrosine kinase inhibitors in patients with non-small-cell lung cancer harboring with RET fusion gene - Research for RET-TKI resistance in NSCLC harboring with RET fusion gene

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021802

Enrollment

Registered

2016-04-12

Start date

2016-05-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small-cell lung cancer harboring with RET fusion gene

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Histologically or cytologically diagnosed NSCLC 3. Unresectable locally advanced or metastatic disease 4. Tumor samples test positive for a RET fusion gene 5. Testing negative for an EGFR mutation 6. Testing negative for an ALK fusion gene

Exclusion criteria

Exclusion criteria: 1. Having previously received alectinib 2.Patients whom an investigator deems ineligible for participation in this study for some other reason.

Design outcomes

Primary

Measure	Time frame
To find out the resistance mechanism to RET-TKI alectinib in NSCLC harboring with RET fusion gene	—

Countries

Japan

Contacts

Public ContactTadaaki Yamada

Cancer Research Institute, Kanazawa University Medical Oncology

tadaakiy@staff.kanazawa-u.ac.jp076-265-2794

Outcome results